Rebastinib

CAS No.

1020172-07-9

MDL No.

MFCD19443646

C₃₀H₂₈FN₇O₃

553.60

InChI Key

WVXNSAVVKYZVOE-UHFFFAOYSA-N

Pack Size	Purity	Price	Availability	Action
-	-	On Request	On Request
Custom synthesis and bulk supply options are available upon request.

Pack Size

Purity

Price

Availability

Action

On Request

Custom synthesis and bulk supply options are available upon request.

Product Information

DCC-2036 is a urea derivative featuring a 3-tert-butyl-1-(quinolin-6-yl)-1H-pyrazol-5-yl group on one nitrogen and a 2-fluoro-4-{[2-(methylcarbamoyl)pyridin-4-yl]oxy}phenyl group on the other. It functions as a tyrosine kinase inhibitor and belongs to the classes of quinolines, pyridinecarboxamides, pyrazoles, organofluorine compounds, and phenylureas.

CAS No.	1020172-07-9
Product Name	Rebastinib

Biological Targets

ABL1

Associated Conditions

neoplasm·breast carcinoma·chronic myelogenous leukemia

* The information provided here is compiled from public sources and is for reference only.

Pricing & Availability

Product Information

Biological Profile

Properties

Biological Targets

Associated Conditions

Documentation

Rebastinib

Pricing & Availability

Product Information

Biological Profile

Properties

Biological Targets

Associated Conditions

Related Articles

The IUPHAR Guide to Immunopharmacology: connecting immunology and pharmacology.

The Selective Tie2 Inhibitor Rebastinib Blocks Recruitment and Function of Tie2 Macrophages in Breast Cancer and Pancreatic Neuroendocrine Tumors.

Identification of potent Yes1 kinase inhibitors using a library screening approach.

The BCR-ABL35INS insertion/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemia.

Documentation

Similar Products

Regorafenib Monohydrate

Regorafenib

WNTinib